AbbVie Inc (ABBV)vsMeihua International Medical Technologies Co Ltd (MHUA)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
MHUA
Meihua International Medical Technologies Co Ltd
$7.61
0.00%
HEALTHCARE · Cap: $425.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 68199% more annual revenue ($61.16B vs $89.55M). MHUA leads profitability with a 10.3% profit margin vs 6.9%. MHUA trades at a lower P/E of 0.3x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MHUA
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
-10.8%
Fair Value
$6.87
Current Price
$7.61
$0.74 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 5.9% — below average capital efficiency
Weak financial health signals
Revenue declined 16.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MHUA
The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : MHUA
The primary concerns for MHUA are Market Cap, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while MHUA is a declining play — different risk/reward profiles.
MHUA carries more volatility with a beta of 0.75 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Meihua International Medical Technologies Co Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?